Harry Thomasian Jr. - 20 Apr 2026 Form 4 Insider Report for PRECIGEN, INC. (PGEN)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
22 Apr 2026, 16:19:25 UTC
Prior SEC filing
20 Mar 2026
Next SEC filing
27 May 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Harry Thomasian, Jr., by Donald P. Lehr, as attorney-in-fact

Key filing fact

Harry Thomasian Jr. filed Form 4 for PRECIGEN, INC. (PGEN) on 22 Apr 2026.

Key facts

  • This page summarizes Harry Thomasian Jr.'s Form 4 filing for PRECIGEN, INC. (PGEN).
  • 2 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 22 Apr 2026, 16:19.

Change

  • Previous filing in this sequence was filed on 20 Mar 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001886301 Primary reporting owner

Thomasian Harry Jr.

Relationship
Chief Financial Officer
Address
20374 SENECA MEADOWS PARKWAY, GERMANTOWN
Signature
/s/ Harry Thomasian, Jr., by Donald P. Lehr, as attorney-in-fact
Signature date
22 Apr 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PGEN transaction Derivative

Option to Purchase Common Stock (Right to Buy)

Award

Transaction value
Shares
+399,000
Change %
Price
$0.000000*
Shares after
399,000
Date
20 Apr 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
399,000
Exercise price
$4.11
Footnotes
F1
PGEN transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares
+120,000
Change %
Price
$0.000000*
Shares after
120,000
Date
20 Apr 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
120,000
Exercise price
Footnotes
F2, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The options vest 25% on May 23, 2027 and in equal monthly installments for three years thereafter.

Footnote F2

Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.

Footnote F3

The RSUs vest 25% on May 23, 2027 and in equal six-month installments for three years thereafter.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .